Vanguard Group Inc Iveric Bio, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $452,036 - $682,706	17,227 Added 0.13%	13,678,616 $538 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $65.5 Million - $86.2 Million	3,509,386 Added 34.57%	13,661,389 $332 Million
Q4 2022 Feb 10, 2023	BUY	$17.24 - $23.95 $69.6 Million - $96.6 Million	4,035,242 Added 65.97%	10,152,003 $217 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.27 Million - $2.51 Million	134,845 Added 2.25%	6,116,761 $110 Million
Q2 2022 Aug 12, 2022	BUY	$9.12 - $18.9 $1.85 Million - $3.84 Million	203,187 Added 3.52%	5,981,916 $57.5 Million
Q1 2022 May 13, 2022	BUY	$12.15 - $16.83 $1.21 Million - $1.68 Million	99,606 Added 1.75%	5,778,729 $97.3 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $11.3 Million - $15.4 Million	817,537 Added 16.82%	5,679,123 $95 Million
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $4.69 Million - $11.6 Million	663,864 Added 15.81%	4,861,586 $79 Million
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $23.9 Million - $30.1 Million	4,197,722 New	4,197,722 $26.5 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.